



RNS: RELEASE

25 June 2026

ImmuPharma PLC
("ImmuPharma" or the "Company")

2026 RESULT OF ANNUAL GENERAL MEETING

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that six of the six resolutions (Resolutions 1 – 6 inclusive) were duly passed by shareholders. Details are contained in the table below.

Resolution	For	% For	Against	% Against	Withheld
1. To receive the accounts of the Company for the year ended 31 December 2025 together with the reports thereon of the directors and auditors of the Company	163,496,678	99	2,252,180	1	365,965
2. To re-appoint Ketan Patel as a director of the Company	156,211,793	98	3,080,916	2	6,822,114
3. To re-appoint Crowe UK LLP as Auditor of the Company	163,482,368	99	2,311,240	1	321,215
4. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting	152,641,450	94	11,960,794	6	1,512,579
SPECIAL RESOLUTION 5. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting	151,322,867	93	13,507,185	7	1,284,771
SPECIAL RESOLUTION 6. That, with effect from the conclusion of the Annual General Meeting, the draft Articles of Association be adopted as the Articles of Association of the Company in substitution for, and to the exclusion of, the Company's existing Articles of Association.	155,666,377	96	7,767,242	4	2,681,204

As at the date of the AGM, the number of issued ordinary shares of the Company was 623,911,379 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.

Ends

For further information please contact:

ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chief Executive Officer and Chairman
Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650

+ 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin

+44 (0) 203 368 3550

Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob Pountney

+44 (0) 203 650 3650/51

SI Capital (Joint Broker)
Nick Emerson

+44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptidebased therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.